ATAI Life Sciences N.V. Common Shares ATAI

$

9
8
7
6
5
4
3
2
1
0
0
9
8
7
6
5
4
3
2
1
0
0
.
9
8
7
6
5
4
3
2
1
0
0
-$0.07 (-4.46%)Past DayToday's Volume:
9
8
7
6
5
4
3
2
1
0
0
9
8
7
6
5
4
3
2
1
0
0
9
8
7
6
5
4
3
2
1
0
0
,
9
8
7
6
5
4
3
2
1
0
0
9
8
7
6
5
4
3
2
1
0
0
9
8
7
6
5
4
3
2
1
0
0
,
9
8
7
6
5
4
3
2
1
0
0

Relative Strength Index (RSI)

- The Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. It is typically used to identify overbought or oversold conditions in financial markets.

- The RSI is calculated using the following formula:

RSI = 100 - (100 / (1 + RS))

Where RS is the ratio of the average gains to the average losses over a specified period.

- The default time period used is 14 days.

- RSI values range between 0 and 100.

RSI values above 70 are considered overbought (indicating a potentially opportune time to sell)

RSI values below 30 are considered oversold (indicating a potentially opportune time to buy)

RSI is not a perfect indicator and should be used in conjunction with other technical analysis tools, this is for informational purposes only and is not a substitute for professional financial advice.

About

Business overview of ATAI Life Sciences N.V. Common Shares (ATAI)
ATAI Life Sciences NV is a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health disorders. Its product candidates include COMP360/Psilocybin therapy, PCN-101/R-ketamine, RL-007/Compound, DMX-1002/Ibogaine, GRX-917/Deuterated etifoxine, VLS-01/DMT, EMP-01/MDMA derivative, RLS-01/Salvinorin A, KUR-101/Deuterated Mitragynine, and DMX-1001/Noribogaine. The business operates geographically in two regions being the United States and Germany.

Key Insights

Critical company metrics and information

  • Latest Closing Price

    $1.51

  • Market Cap

    $292.93 Million

  • Price-Earnings Ratio

    -1.89

  • Total Outstanding Shares

    193.99 Million Shares

  • Total Employees

    83

  • Dividend

    No dividend

  • IPO Date

    June 18, 2021

  • SIC Description

    Pharmaceutical Preparations

  • Primary Exchange

    NASDAQ

  • Type

    Common Stock

  • Headquarters

    Wallstrasse 16, Berlin, 2M, 10179

  • Homepage

    https://www.atai.life

Historical Stock Splits

Execution DateSplit Amount
No Historical Stock Splits

Cash Flow Statement

October 1, 2023 to September 30, 2024
MetricValue
Net Cash Flow, Continuing$-31.56 Million
Net Cash Flow From Investing Activities$51.79 Million
Net Cash Flow From Operating Activities, Continuing$-80.10 Million
Net Cash Flow From Operating Activities$-80.10 Million
Net Cash Flow$-31.56 Million
Net Cash Flow From Investing Activities, Continuing$51.79 Million

Income Statement

October 1, 2023 to September 30, 2024
MetricValue
Income/Loss From Continuing Operations After Tax$-127.81 Million
Operating Expenses$106.32 Million
Participating Securities, Distributed And Undistributed Earnings/Loss, Basic$0
Costs And Expenses$127.87 Million
Income/Loss From Continuing Operations Before Tax$-127.54 Million
Net Income/Loss$-130.20 Million

Comprehensive Income

October 1, 2023 to September 30, 2024
MetricValue
Comprehensive Income/Loss$-131.25 Million
Comprehensive Income/Loss Attributable To Parent$-129.61 Million
Comprehensive Income/Loss Attributable To Noncontrolling Interest$-1.64 Million
Other Comprehensive Income/Loss$-1.05 Million

Balance Sheet

October 1, 2023 to September 30, 2024
MetricValue
Current Assets$114.07 Million
Equity$146.32 Million
Long-term Debt$20.34 Million
Fixed Assets$865,000
Liabilities$51.20 Million
Equity Attributable To Noncontrolling Interest$596,000

Historical Dividends

Announcement DatePayment DateRecord DateAmountFrequency
No historical dividends

Recent Headlines From The Web

Latest news, press releases, and media coverage about ATAI from trusted financial sources
    All TickersEarnings CalendarNews ArticlesAbout UsPrivacy & Cookies Info

    ⓒ 2025 Financhle. All Rights Reserved.